Premia Builds a Strong Portfolio of Student Residences

Developing student housing is a strategic priority for Premia, as the company plans to create five new facilities in regional cities. The company aims to build a portfolio worth €1 billion over the next five years. Specifically, as revealed by Kostas Markazos during the April 8, 2025 analyst briefing, two new units will be developed in Xanthi, while one each will be built in Larissa, Volos, and Rhodes, with the goal of creating a total of 500 beds. Additionally, Premia is close to acquiring a second property in Volos for student residences, strengthening its presence in the region. The company also enhances its portfolio in the education sector by adding a new school building in Artemida, covering 2,133 sqm, which has already been leased to the municipality. In Thessaloniki, Premia acquired two office buildings with a total area exceeding 7,000 sqm; one is already rented to the Land Registry Office, while the second is being renovated and is expected to be leased by the end of 2025. To boost its investment capacity, Premia will increase its share capital by €30-40 million in the coming months. The new funds will be used to further diversify its shareholder base and finance new investments. The investment plan for 2025 involves €50 million in investments, of which €17 million have already been spent. During 2024, Premia completed several significant projects, confirming its rapid growth trajectory. Notably, operations began at the green office complex in Tavros, housing the central services of ADED, and modern student residences in Xanthi. The company also acquired two 4-star hotels in Rhodes and Crete with a combined capacity of 796 rooms, leased to Nordic Leisure TravelGroup (NLTG), and a logistics facility in Aspropyrgos covering 11,301 sqm, leased to Iron Mountain Hellas A.E. Selective sales of properties in Katerini and Santorini yielded significant profits, along with the redevelopment of an existing property in Pikermi, which will include office spaces and a pharmaceutical manufacturing facility leased to GENEPHARM, with completion expected in Q2 2025. Premia anticipates a year of exceptional growth, driven by the completion of major investments from the previous year and ongoing or planned new investments that are expected to enhance the group’s financial performance. For 2025, consolidated revenues are estimated between €34-35 million, with a substantial increase in operational profitability (Adjusted EBITDA) projected at €22-23 million.